Literature DB >> 29106493

Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?

F Gelsomino1,2, M Fiorentino3, M Zompatori4, A Poerio4, B Melotti2, F Sperandi2, M Gargiulo5, C Borghi6, A Ardizzoni2,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29106493     DOI： 10.1093/annonc/mdx718

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

Review 1.  Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.

Authors:  Jacqueline T Vuong; Ashley F Stein-Merlob; Arash Nayeri; Tamer Sallam; Tomas G Neilan; Eric H Yang
Journal:  J Am Coll Cardiol       Date:  2022-02-15       Impact factor: 24.094

2.  Possible Precipitation of Acute Coronary Syndrome with Immune Checkpoint Blockade: A Case Report.

Authors:  Rajeev Masson; Gopi Manthripragada; Raymond Liu; Jahan Tavakoli; Kenny Mok
Journal:  Perm J       Date:  2020-12

3.  The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer.

Authors:  Lili Zhang; Kerry L Reynolds; Alexander R Lyon; Nicolas Palaskas; Tomas G Neilan
Journal:  JACC CardioOncol       Date:  2021-01-12

4.  Identification of immune cell infiltration and diagnostic biomarkers in unstable atherosclerotic plaques by integrated bioinformatics analysis and machine learning.

Authors:  Jing Wang; Zijian Kang; Yandong Liu; Zifu Li; Yang Liu; Jianmin Liu
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

5.  Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.

Authors:  Udo Hoffmann; Tomas G Neilan; Zsofia D Drobni; Raza M Alvi; Jana Taron; Amna Zafar; Sean P Murphy; Paula K Rambarat; Rayma C Mosarla; Charlotte Lee; Daniel A Zlotoff; Vineet K Raghu; Sarah E Hartmann; Hannah K Gilman; Jingyi Gong; Leyre Zubiri; Ryan J Sullivan; Kerry L Reynolds; Thomas Mayrhofer; Lili Zhang
Journal:  Circulation       Date:  2020-10-02       Impact factor: 29.690

Review 6.  Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem.

Authors:  Kikkie Poels; Suzanne I M Neppelenbroek; Marie José Kersten; M Louisa Antoni; Esther Lutgens; Tom T P Seijkens
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.